Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022

Overseas Treatment of Latent Tuberculosis Infection in US–Bound Immigrants

Amera KhanComments to Author , Christina R. Phares, Hoang Lan Phuong, Dang Thi Kieu Trinh, Ha Phan, Cindy Merrifield, Phan Thi Hong Le, Quach Thi Kim Lien, Sooc Ngoc Lan, Phan Thi Kim Thoa, Le Tran Minh Thu, Tiffany Tran, Cuc Tran, Lucy Platt, Susan A. Maloney, Nguyen Viet Nhung, Payam Nahid, and John E. Oeltmann
Author affiliations: Stop TB Partnership, Geneva, Switzerland (A. Khan); London School of Hygiene and Tropical Medicine, London, UK (A. Khan, L. Platt); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.R. Phares, C. Tran, S.A. Maloney, J.E. Oeltmann); Cho Ray Hospital Visa Medical Clinic, Ho Chi Minh City, Vietnam (H.L. Phuong, D.T.K. Trinh, P.T.H. Le, Q.T.K. Lien, S.N. Lan, P.T.K. Thoa, L.T.M. Thu); Vietnam National TB Program/University of California–San Francisco Research Collaboration, Hanoi, Vietnam (H. Phan, C. Merrifield, T. Tran, N.V. Nhung, P. Nahid); University of California–San Francisco, San Francisco, California, USA (H. Phan, C. Merrifield, P. Nahid); Vietnam National TB Program, Hanoi (N.V. Nhung)

Main Article

Table 4

Reasons for declining to initiate 3HP and discontinuing treatment among participants in the Preventing Tuberculosis Overseas Pilot Study of US immigrant visa applicants, Vietnam, 2018–2019*

No. (%) participants
Declined to initiate 3HP 148 (100)
Not enough time; planned to depart for United States immediately after receiving visa 99 (67)
Preferred to take medicine in United States 23 (16)
Inconvenient to go to hospital for treatment: distance, time, or both 22 (15)
Concerned about adverse events from medicine 7 (5)
Did not feel sick
3 (2)
Treatment discontinued 36 (100)
Participant decided on own to stop because of grade 1 or 2 adverse events 18 (50)
Participant decided on own because too busy or moving to United States earlier 5 (14)
Identified as contact to a person with MDR or isoniazid-resistant TB or had extrapulmonary TB diagnosed after treatment initiation 5 (14)
Serious adverse event: grade 3 event, elevated liver function test, or both 5 (14)
Lost to follow-up in United States 3 (8)

*MDR, multidrug-resistant; TB, tuberculosis; 3HP, 3-mo regimen of isoniazid and rifapentine.

Main Article

Page created: December 13, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.